Akanda Soared 200% on Schedule III News: Inside the Cannabis Penny-Stock Pop

When the U.S. Department of Justice's Schedule III order for state-licensed medical marijuana hit the wires on April 22–23, 2026, the most interesting story in cannabis equities was not Tilray, Canopy Growth, or the MSOS ETF — even though all three rallied. The most interesting story was a small-cap, low-priced cannabis name called Akanda Corp (NASDAQ: AKAN). Shares of Akanda exploded more than 200% in a single trading session before partially reversing, in a textbook display of how penny-stock cannabis names trade against macro policy news. For investors trying to read the post-rescheduling tape, Akanda's move is a useful case study in what these rallies actually mean.

What Happened to Akanda in One Trading Session

The mechanics are straightforward. On the morning of April 22, headlines began crossing that the DOJ would issue a final rule reclassifying state-licensed medical cannabis from Schedule I to Schedule III. Akanda shares, which had been trading at depressed levels on relatively thin volume, spiked sharply at the open. By the time the dust settled, AKAN had posted intraday gains north of 200%. Multi-state operators and cannabis ETFs rallied alongside it but at far smaller magnitudes — typical for a name with a much larger float and deeper analyst coverage.

The size of the move was eye-catching, but the pattern was familiar. Small-cap and penny-stock cannabis names tend to amplify policy news in both directions. When a positive catalyst hits, lower share counts and thinner books mean buying pressure pushes prices up faster. When the catalyst is digested or partially walked back, the same illiquidity drives sharper retracement. By the close of the session, Akanda had given back a meaningful chunk of its peak gain — though it still ended the day substantially higher than the previous close.

Why Schedule III Mattered for Cannabis Equities

Cannabis stocks have been waiting on a clear federal catalyst for years, and Schedule III is the closest thing the sector has had to one. The single most material piece of the DOJ order is what it does to Section 280E of the Internal Revenue Code. Under 280E, businesses trafficking in Schedule I or Schedule II controlled substances cannot deduct ordinary business expenses against gross income for federal tax purposes. The result, for compliant U.S. plant-touching operators, has been effective federal tax rates often running between 60% and 80% — a structural drag the rest of corporate America does not face.

By moving state-licensed medical marijuana to Schedule III, the DOJ removed the statutory hook for 280E as it applies to that lane of operations as of April 22, 2026. For multi-state operators with significant medical-licensed exposure, the math improves dramatically — analysts have estimated effective tax rates falling toward the 20% to 30% range. That is a margin and cash-flow story, and the market took it seriously, hence the broad sector-wide rally on the news.

The reason Akanda's reaction was outsized has less to do with Akanda specifically and more to do with positioning, float, and risk appetite. When a sector-wide catalyst hits, traders chasing leverage to the macro story often gravitate to small-cap names where percentage moves are largest.

What Akanda Actually Does

It is worth grounding the trading story in the underlying business. Akanda Corp is a small, internationally-oriented cannabis company that has historically focused on cultivation, export, and medical cannabis distribution outside the United States. It is not a U.S. multi-state operator with directly addressable exposure to the 280E tax savings. That is an important distinction. The fundamental beneficiaries of the DOJ order — the operators whose effective tax rates will visibly fall on next quarter's filings — are U.S. plant-touching MSOs.

Akanda's price reaction was therefore more sentiment-driven than fundamentals-driven. When a sector catalyst sweeps through cannabis names, low-priced equities with cannabis-keyword exposure tend to move first and most violently. That is a pattern any reader who has watched the sector for more than one cycle has seen before.

The Reversal Is Part of the Story

A clean read of penny-stock catalysts has to include the second half of the day. Many of the most leveraged cannabis trades reversed meaningfully into the close of the rescheduling session and traded sideways or down in the days that followed. Cannabis stocks swung wildly on U.S. rescheduling news, with broad-market moves that looked dramatic on a one-day chart and far more mixed on a one-week chart.

Why does that happen? A few reasons. First, the order rescheduled state-licensed medical cannabis specifically, not adult-use cannabis. The bigger U.S. market — recreational — remains in Schedule I pending the broader DEA hearing scheduled for June 29, 2026. Investors who expected an across-the-board rescheduling had to recalibrate. Second, traders who took penny-stock leverage took profits quickly. Third, lawsuits — including a stated intention by Smart Approaches to Marijuana to challenge the order — added uncertainty about implementation timing.

Together, those forces produced the classic post-news round-trip that defines low-float catalyst trading.

What This Means for Cannabis Investors

The general direction of the U.S. cannabis equity story has improved. A federal Schedule III for medical marijuana removes a major tax penalty for medical-licensed operators, eases research barriers, and signals continued federal motion. The June 29 DEA hearing on broader rescheduling is the next material catalyst. If that process points toward bringing recreational cannabis to Schedule III as well, the tax-relief story extends to the much larger adult-use market.

For investors trying to play that thesis, the practical lesson from Akanda's session is that not every cannabis ticker is exposed equally. ETFs like MSOS and large U.S. MSOs have direct, visible exposure to 280E relief on their medical operations. Small-cap, internationally-focused names like Akanda are sentiment-correlated to U.S. cannabis policy but do not necessarily benefit fundamentally from a U.S. tax change. Reading the difference is how investors avoid mistaking a one-day pop for a durable thesis.

This article is for informational purposes only and is not investment advice. Cannabis equities are volatile, and policy-driven moves in particular carry significant downside risk.

Key Takeaways

• Akanda Corp shares spiked over 200% in a single session on the April 22 DOJ Schedule III rescheduling news.
• The structural story for the sector is the removal of 280E for state-licensed medical cannabis — a major margin and cash-flow boost for U.S. multi-state operators.
• Akanda's outsized move was sentiment-driven; the company is internationally focused and not a direct U.S. 280E beneficiary.
• Many cannabis stocks reversed sharply into the close, a familiar pattern in policy-driven catalyst sessions.
• The June 29 DEA hearing on broader rescheduling is the next catalyst the cannabis equity market is watching.

Explore cannabis news, find dispensaries, and join the community at Budpedia.

While the equity market waits for the DEA hearing, shoppers can find a dispensary near you on Budpedia — 7,400+ verified medical and recreational retailers across every legal state.